Position in EXEL
as of Mar 31, 2026
· filed May 13, 2026
Position Value
$331,368
-$7,569 QoQ
Shares Held
7,726
-0.1% QoQ
Ownership
0.003%
of shares outstanding
% of Portfolio
0.06%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2022
7 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in EXEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Truvestments Capital LLC holds $1,930,996 across 60 Biotechnology names. EXEL ranks #1 (17.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | EXEL |
Exelixis, Inc.
This page
|
7,726 | $331,368 | |
| 2 | CRVS |
Corvus Pharmaceuticals, Inc.
|
10,257 | $150,059 | |
| 3 | CTMX |
CytomX Therapeutics, Inc.
|
27,428 | $128,911 | |
| 4 | PTGX |
Protagonist Therapeutics, Inc
|
1,161 | $122,369 | |
| 5 | ROIV |
Roivant Sciences Ltd.
|
3,680 | $101,936 | |
| 6 | KALV |
KalVista Pharmaceuticals, Inc.
|
4,684 | $94,288 | |
| 7 | BBIO |
BridgeBio Pharma, Inc.
|
1,155 | $85,770 | |
| 8 | DBVT |
DBV Technologies S.A.
|
3,892 | $81,303 |
All Filings in EXEL
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $331,368 | 7,726 | Shares | Sole | 2026-05-13 | |
| 2025-12-31 | $338,937 | 7,733 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $310,906 | 7,528 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $22,392 | 508 | Shares | Sole | 2025-08-13 | |
| 2022-12-31 | $1,876 | 117 | Shares | Sole | 2023-02-14 | |
| 2022-09-30 | $1,834 | 117 | Shares | Sole | 2022-11-15 | |
| 2022-06-30 | $2,435 | 117 | Shares | Sole | 2022-08-09 | |
| No filing history on record for this holder in this stock. | ||||||